# A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants

> **NCT02692677** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** JNJ-42756493

## Key facts

- **NCT ID:** NCT02692677
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02692677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02692677, "A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02692677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*